[4-(2-{4-[2-(4-bromobenzyl)-3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}vinyl)phenyl]dimethylamine | 902143-21-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: [4-(2-{4-[2-(4-bromobenzyl)-3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}vinyl)phenyl]dimethylamine
• 英文别名: 4-[(E)-2-[4-[2-[(4-bromophenyl)methyl]-3-[tert-butyl(dimethyl)silyl]oxypropoxy]phenyl]ethenyl]-N,N-dimethylaniline
• CAS: 902143-21-9
• 化学式: C₃₂H₄₂BrNO₂Si
• 分子量: 580.68
• InChiKey: WZBQYGAQMMIEFA-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.95
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(2-{4-[2-(4-bromobenzyl)-3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}vinyl)phenyl]dimethylamine 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 以59%的产率得到2-(4-Bromo-benzyl)-3-{4-[(E)-2-(4-dimethylamino-phenyl)-vinyl]-phenoxy}-propan-1-ol
  参考文献：
  名称：

  F-18 Stilbenes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain

  摘要：

  Imaging agents targeting beta-amyloid (A beta) may be useful for diagnosis and treatment of patients with Alzheimer's disease (AD). Compounds 3e and 4e are fluorinated stilbene derivatives displaying high binding affinities for A beta plaques in AD brain homogenates (K-i = 15 +/- 6 and 5.0 +/- 1.2 nM, respectively). In vivo biodistributions of [F-18]3e and [F-18]4e in normal mice exhibited excellent brain penetrations (5.55 and 9.75% dose/g at 2 min), and rapid brain washouts were observed, especially for [F-18]4e (0.72% dose/g at 60 min). They also showed in vivo plaque labeling in APP/PS1 or Tg2576 transgenic mice, animal models for AD. Autoradiography of postmortem AD brain sections and AD homogenate binding studies confirmed the selective and specific binding properties to A beta plaques. In conclusion, the preliminary results strongly suggest that these fluorinated stilbene derivatives, [F-18]3e and [(18F)]4e, are suitable candidates as A beta plaque imaging agents for studying patients with AD.

  DOI：

  10.1021/jm050166g
• 作为产物：
  描述：

  2-(4-bromobenzyl)propane-1,3-diol 在 吡啶 、 四溴化碳 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 [4-(2-{4-[2-(4-bromobenzyl)-3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}vinyl)phenyl]dimethylamine
  参考文献：
  名称：

  F-18 Stilbenes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain

  摘要：

  Imaging agents targeting beta-amyloid (A beta) may be useful for diagnosis and treatment of patients with Alzheimer's disease (AD). Compounds 3e and 4e are fluorinated stilbene derivatives displaying high binding affinities for A beta plaques in AD brain homogenates (K-i = 15 +/- 6 and 5.0 +/- 1.2 nM, respectively). In vivo biodistributions of [F-18]3e and [F-18]4e in normal mice exhibited excellent brain penetrations (5.55 and 9.75% dose/g at 2 min), and rapid brain washouts were observed, especially for [F-18]4e (0.72% dose/g at 60 min). They also showed in vivo plaque labeling in APP/PS1 or Tg2576 transgenic mice, animal models for AD. Autoradiography of postmortem AD brain sections and AD homogenate binding studies confirmed the selective and specific binding properties to A beta plaques. In conclusion, the preliminary results strongly suggest that these fluorinated stilbene derivatives, [F-18]3e and [(18F)]4e, are suitable candidates as A beta plaque imaging agents for studying patients with AD.

  DOI：

  10.1021/jm050166g

文献信息

• F-18 Stilbenes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain
  作者：Wei Zhang、Shunichi Oya、Mei-Ping Kung、Catherine Hou、Donna L. Maier、Hank F. Kung

  DOI：10.1021/jm050166g

  日期：2005.9.1

  Imaging agents targeting beta-amyloid (A beta) may be useful for diagnosis and treatment of patients with Alzheimer's disease (AD). Compounds 3e and 4e are fluorinated stilbene derivatives displaying high binding affinities for A beta plaques in AD brain homogenates (K-i = 15 +/- 6 and 5.0 +/- 1.2 nM, respectively). In vivo biodistributions of [F-18]3e and [F-18]4e in normal mice exhibited excellent brain penetrations (5.55 and 9.75% dose/g at 2 min), and rapid brain washouts were observed, especially for [F-18]4e (0.72% dose/g at 60 min). They also showed in vivo plaque labeling in APP/PS1 or Tg2576 transgenic mice, animal models for AD. Autoradiography of postmortem AD brain sections and AD homogenate binding studies confirmed the selective and specific binding properties to A beta plaques. In conclusion, the preliminary results strongly suggest that these fluorinated stilbene derivatives, [F-18]3e and [(18F)]4e, are suitable candidates as A beta plaque imaging agents for studying patients with AD.